Mdma-at-bn
Phase 1
Mdma-at-bn is one of 18 therapeutic programs targeting Bulimia Nervosa. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
17
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
18 competitors in Bulimia Nervosa
#DrugCompanyPhaseTrials
1Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Prometrium
FerringApproved
Cysteine Hydrochloride
NovartisPhase 3
Antidepressants
Johnson & JohnsonApproved
Estrace
Novo NordiskPhase 2
Positron Emission Tomography (PET)
CCentre Hospitalier Universitaire de Saint Etienne
Approved
E-Mycin
AAzurity Pharmaceuticals
Phase 2
Lupron
EEastern Cooperative Oncology Group
Phase 2
Lisdexamfetamine Dimesylate
TakedaPhase 2
Micronized Progesterone
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Mdma-at-bn. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]